Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck says it will acquire London-based Verona Pharma for about US$10bil, gaining a promising respiratory treatment as it ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Merck & Co. said Wednesday it will acquire London-based Verona Pharma in a $10 billion all-cash deal, bolstering its respiratory treatment portfolio as the company moves to reduce long-term dependence ...

Pharmaceutical giant Merck & Co. (MRK) is buying British lung therapy firm Verona Pharma (VRNA) for $10 billion U.S. In a written statement, Merck said the deal will strengthen its respiratory ...

US drugmaker Merck is nearing a deal worth about $10 billion to buy Verona Pharma, a company focused on therapies for lung ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...